RG 7882

Drug Profile

RG 7882

Alternative Names: D-4064A; DMUC 4064A; RG7882

Latest Information Update: 19 Oct 2015

Price : $50

At a glance

  • Originator Genentech
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Membrane protein inhibitors; Tumour-associated carbohydrate antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 19 Oct 2015 Phase-I development is ongoing in USA for ovarian and pancreatic cancer
  • 06 Nov 2008 Genentech suspends a phase I trial in Peritoneal, Ovarian and Fallopian tube cancers in USA (NCT00753480)
  • 29 Sep 2008 Phase-I clinical trials in Peritoneal cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top